Novo Nordisk stock (NVO) jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first quarter and despite a slight cut to its sales forecast for the year.

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for ... The Danish drugmaker – which has its U.S. headquarters in Plainsboro – seeks regulatory approval for ...

Novo Nordisk now forecasts 2025 sales growth between 13% and 21%, and operating profit growth between 16% and 24% at constant exchange rates (CER), down 3 and 5 percentage points respectively from ...

Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call ... Next slide, please. Building on the learnings from REDEFINE 1 and REDEFINE 2 trials, we have extended the duration of redefined ...

LONDON/COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to ...

Novo Nordisk's profitability and growth in emerging markets, coupled with a forward P/E ratio of 16.35x, make it an undervalued investment opportunity. Market concerns over minor market share ...

LONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President ...